Last reviewed · How we verify
Y-3 for injection（40mg）
At a glance
| Generic name | Y-3 for injection（40mg） |
|---|---|
| Sponsor | Neurodawn Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects (PHASE1)
- The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction (NA)
- Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y-3 for injection（40mg） CI brief — competitive landscape report
- Y-3 for injection（40mg） updates RSS · CI watch RSS
- Neurodawn Pharmaceutical Co., Ltd. portfolio CI